Depo-Provera Lawsuit (November 2025)

Depo-Provera is an injectable contraceptive used by millions of women globally. It contains medroxyprogesterone acetate, a synthetic hormone that prevents pregnancy by stopping ovulation and thickening cervical mucus. Administered by a healthcare professional every three months, it offers a long-term birth control option without the need for daily pills or invasive devices.

Since the U.S. Food and Drug Administration (FDA) approved Depo-Provera in 1992, it has been a popular choice for contraception. However, as its use spread, reports of significant side effects surfaced, leading to concerns about its safety. Some women have experienced severe complications, such as bone density loss, an increased risk of osteoporosis, and cardiovascular issues.

As reports of these severe side effects surfaced, many women began taking legal action against Pfizer, claiming inadequate warnings about the drug’s potential risks. In the following sections, we explore these health risks, the lawsuits, and the available legal options for those harmed by Depo-Provera.

Depo-Provera Lawsuit Updates and Latest News

Earlier this year, PubMed Central released a study discussing the possible link between synthetic hormones and intracranial meningioma brain tumors. Once Depo-Provera users connected the dots, they realized their tumors might be caused by taking the contraceptive drug. Many women are now filing suit to recover the expenses they have incurred because they were never warned about the dangers they faced when taking Depo-Provera.

At Dolman Law Group, we are closely monitoring these cases and meeting with injured women who may be eligible to bring legal action against Pfizer or other companies responsible for their damages. The Dolman team will provide regular updates to keep you informed about the latest news and updates related to this litigation. Be sure to bookmark this page and return often for more information.

November 1, 2025 – More than 1,300 Lawsuits Pending in the Federal MDL, New Study Supports Link Between Depo-Provera and Brain Tumors

If you’ve used Depo-Provera and later faced a meningioma brain tumor diagnosis, you may be eligible to join the more than 1,300 women whose federal MDL claims are now pending. Or, your claim might be more like the hundreds who have filed in state courts across Delaware, New York, California, and beyond.

Case Counts in the Past Month

• Federal MDL growth: As of October 20, 2025, 1,346 Depo-Provera lawsuits were pending in federal multidistrict litigation.
  
• State-court filings: Over 439 additional claims are active in state courts, with 332 in Delaware, 78 in New York, and others in California, Illinois, Pennsylvania, and more.

A Recent Study Helps Plaintiffs’ Argument

A recent population‐based study confirmed what many plaintiffs have felt: long-term Depo-Provera use is linked to a significantly higher risk of developing meningiomas compared to other contraceptives or non-users. While Pfizer is still contesting liability, these findings strengthen the injured plaintiffs’ voice in court.

Key Dates Approaching

• Expert testimony & depositions: Scheduled for late 2025 into early 2026.
  
• Next MDL conference: October 24, 2025, when Judge Rodgers will review discovery progress.
  

At Dolman Law Group, we understand the fear and frustration you may be feeling. Reach out today for a free, no-obligation consultation. We’ll listen to your story, review your records, and help you decide the best way to protect your rights and your future.

OCTOBER 1, 2026 – NEW SCIENCE AND STRONG LEGAL PUSHBACK

If you’ve used Depo-Provera and been diagnosed with a brain tumor, you have good reason to watch this litigation closely. In the past month, the litigation has been moving quickly, the science is getting stronger, and a major legal fight is unfolding in federal court.

Pfizer Tries to Shut Down the Case Before Trial

At the beginning of September, Pfizer filed a legal motion asking the court to dismiss the lawsuits before they reach the discovery phase. Their argument is based on a concept called federal preemption. Pfizer says that because the FDA declined to approve a label change in 2024, the company cannot be sued under state law for failing to warn patients about the tumor risks.

Here’s what happened:

• In 2024, Pfizer submitted a proposed warning to the FDA about the risk of meningioma brain tumors.
  
• The FDA responded with a Complete Response Letter, saying the evidence did not justify the label change.
  
• Pfizer argues that federal law blocks any lawsuits that say it should have warned sooner or more clearly.
  

If the judge agrees, many of the claims in this litigation could be dismissed, not because the risks weren’t real, but because of how the company presents its regulatory history.

However, Plaintiffs Say Pfizer Had Other Options

On September 22, attorneys for the women injured by Depo-Provera filed a powerful response. They argue that Pfizer’s preemption argument doesn’t hold up because:

• The FDA never rejected a strong, risk-based warning, only a vague and overly general label change.
  
• Pfizer didn’t share all relevant evidence with the FDA, including decades of studies and stronger warnings used in other countries.
  
• The company still could have strengthened the label independently using a legal process called CBE, which it chose not to pursue.
  
• Nothing in federal law prevented Pfizer from warning patients or promoting safer alternatives, such as the lower-dose SubQ version of the drug.
  

This is a critical moment in the case. A ruling on preemption is expected soon, and it could decide whether these lawsuits move forward or are stopped in their tracks.

Major Study Finds Increased Brain Tumor Risk for Depo-Provera Users

One of the biggest developments this month comes from a new Cleveland Clinic study published in JAMA Neurology. The study examined health records from over 10 million women and found that long-term use of Depo-Provera is linked to a much higher risk of intracranial meningioma, a type of brain tumor.

Key findings include:

• Women who used Depo-Provera for more than 4 years, especially after age 31, had a 2.43x higher risk of developing brain tumors.
  
• Other forms of birth control did not show the same risk.
  
• For every 1,100 women exposed, one extra tumor is expected to develop.
  

This is not a small concern. The study adds major credibility to what many women have experienced firsthand and gives the court a strong scientific basis to reject Pfizer’s defense that the risks weren’t proven.

Over 800 Lawsuits Filed and Counting

The number of lawsuits continues to grow. As of last month, there are now more than 800 Depo-Provera cases filed in federal court. Women from all over the country are coming forward to share their stories of surgery, neurological issues, and life-changing diagnoses that they never saw coming.

Kaiser Permanente Named as Defendant in California Lawsuit

One of the newest lawsuits was filed in California, and it doesn’t just name Pfizer, it also includes Kaiser Permanente as a defendant. The woman in that case was prescribed Depo-Provera at Kaiser facilities between 2016 and 2024 and later developed multiple brain tumors.

Her lawsuit alleges:

• Kaiser promoted Depo-Provera as a safe contraceptive even though it knew (or should have known) about the risks.
  
• The health system presented its safety reviews as independent and trustworthy, but failed to protect patients.
  
• One of the plaintiff’s many tumors required surgery, while others are still being monitored with lifelong imaging.
  

This may be the beginning of a new phase in the litigation, where healthcare providers themselves are also held accountable.

At Dolman Law Group, we know how hard it is to face a diagnosis like this, and how overwhelming it can feel to ask legal questions while trying to heal. If you or someone you love used Depo-Provera and later developed a brain tumor, you deserve answers. We’re here to help you understand your options and connect you with compassionate legal support.

SEPTEMBER 1, 2025 – INJURED WOMEN CONTINUE TO STEP FORWARD IN DEPO-PROVERA LAWSUITS

If you’ve been diagnosed with a brain tumor after receiving Depo-Provera injections, you are not imagining the connection. Hundreds of women across the country are now filing lawsuits, sharing similar experiences and demanding answers from the company that made this drug a routine part of their lives.

More Cases Filed Across the U.S.

The number of federal lawsuits continues to grow, with over 550 cases now pending in the Depo-Provera multidistrict litigation (MDL) based in Florida. Dozens more have been filed in state courts, including a new Delaware case involving 100 women. Others are moving forward in New York, California, Illinois, and Pennsylvania.

One of the latest cases involves a woman from New Jersey, who began using Depo-Provera for birth control back in 2013. A decade later, she was diagnosed with a serious brain tumor and underwent invasive surgery. Only afterward did she learn that the risks of this drug had been quietly documented overseas for years, but never properly disclosed in the U.S..

Could All of These Cases Be Dismissed?

Pfizer, the company behind Depo-Provera, is trying to avoid these lawsuits altogether by claiming that the FDA’s rejection of a warning label in 2024 means they cannot be sued. In simple terms, they’re saying that because the government didn’t approve a vague warning Pfizer suggested, they had no legal obligation to do more.

But many women and their attorneys disagree. They say Pfizer could have done more to clearly communicate the risk and that the law still allows drug companies to act when new safety concerns emerge.

The judge should decide this fall whether to allow these lawsuits to continue. But most legal experts believe that Pfizer’s argument is unlikely to succeed and that the women who were harmed will have their day in court.

Why Some Women Haven’t Filed Yet

Behind the scenes, the court has also started asking why some law firms are holding off on filing additional claims. The concern is that if a ruling comes down in Pfizer’s favor, late-filed cases could be shut out. But lawyers say this cautious approach is meant to protect clients, not hide them. Many believe the best solution is to create a transparent system where all potential claims are logged, even if they aren’t formally filed right away.

Finding Support and Taking Action

These lawsuits aren’t just about legal arguments. They’re about real women, many of whom are still healing, still unsure what the future holds, and still wondering why they weren’t warned.

If you received Depo-Provera and were later diagnosed with a brain tumor, you may be eligible to join this growing group of women seeking justice. At Dolman Law Group, we understand how overwhelming this process can feel. That’s why we’re here to listen, guide, and connect you with the legal support you need to move forward.

You deserve answers and justice. Trust Dolman Law Group to fight for you.

AUGUST 1, 2025 – WRONGFUL DEATH CLAIM JOINS THE MDL, STATE AND FEDERAL FILINGS INCREASE

Another Family Comes Forward After Tragic Loss

A new wrongful death lawsuit was filed by the family of a Texas woman who passed away suddenly in October 2024 at the age of 47. She had used Depo-Provera for years. According to the lawsuit, an autopsy revealed that her death was caused by a hemorrhage from a brain tumor that had never been diagnosed. Her family believes the tumor was linked to the contraceptive injections she received for much of her adult life.

For families dealing with the loss of a loved one or the shock of a brain tumor diagnosis, this case is a heartbreaking reminder of how serious the risks may be.

The Legal Fight Is Gaining Strength

More than 550 lawsuits are now pending in federal court. While most cases are consolidated in the MDL (multidistrict litigation) in Florida, smaller groups of lawsuits are appearing in state courts across the country. New York has the largest state-level group so far, with over 60 cases waiting to be assigned to a coordinating judge. California is also seeing new filings, and more cases are expected to emerge in the months ahead.

This growing legal pressure sends a message to Pfizer: women are standing up and demanding accountability.

Staying on Track with Paperwork Matters

Meeting court deadlines is incredibly important for women who’ve filed a claim. The MDL judge is requiring timely completion of official questionnaires, which gather information about the plaintiff’s Depo-Provera use and medical history. If deadlines are missed, the court may issue a “Show Cause” order, which is a formal warning that a case could be dismissed without proper follow-up.

Thankfully, women who are part of the medical monitoring class have a lighter burden. These claimants only need to show that they used Depo-Provera; they don’t have to prove they’ve already suffered harm to remain part of the litigation.

If you’ve been diagnosed with a brain tumor, you may be scared and unsure where to turn. At Dolman Law Group, we understand what’s at stake. If you’ve been affected by Depo-Provera and are ready to explore your legal options, we’re here to help.

July 1, 2025 – 400+ Women Have Filed Depo-Provera Brain Tumor Lawsuits, Federal and State Cases Continue

If you’re one of the many women who trusted Depo-Provera for birth control and later faced a brain tumor diagnosis, you are not alone. Across the country, more women are coming forward every day, joining a growing wave of lawsuits against the makers of this drug. Many are sharing stories that sound all too familiar: years of regular injections, unexplained symptoms, and eventually, life-changing diagnoses.

Hundreds of Lawsuits, One Common Thread

As of this month, more than 400 women have filed federal lawsuits, and many others are pursuing claims in state courts across the country. Most of these women are living with or recovering from intracranial meningiomas—serious brain tumors that have left them facing surgery, radiation, hearing loss, memory problems, emotional trauma, and financial stress.

One of the newest cases comes from Massachusetts, where a woman diagnosed with a large brain tumor in 2022 now faces ongoing neurological and psychological effects after years of Depo-Provera use. Her story echoes many others and is proof that what you’re experiencing is real and that you’re not the only one asking hard questions about this drug.

A Crucial Legal Battle Ahead

A key moment in the legal process is coming up this fall. On September 29, 2025, a federal judge will hear arguments about whether Pfizer, the maker of Depo-Provera, can avoid responsibility because the FDA did not approve certain warning label changes. Pfizer says federal law shields them from lawsuits like these. But the women filing these claims argue that Pfizer had a duty to act when new science showed the dangers, even if regulators were slow to respond.

This hearing could shape the future of the entire case. But for now, the fight continues, and so does the effort to make sure your voice is heard.

State Lawsuits Are Growing Too

While the federal litigation is gaining strength, similar cases are being filed in state courts. Right now, New York has the largest number of cases, and California is not far behind. Even though one effort to coordinate cases in Pennsylvania recently fell through, other states are moving full speed ahead.

This means that no matter where you live, there may be legal options available to you.

Gathering the Proof You Need

Many women are understandably worried about tracking down proof that they received Depo-Provera, especially if it was years ago. Fortunately, the court has put a system in place to help. Our lawyers are working hard to request records from clinics, pharmacies, and insurance companies. Even if your doctor no longer has your chart, there are ways to confirm your use of the drug and move your case forward.

And if medical providers don’t cooperate, the court may step in to make sure you aren’t denied access to critical records.

June 1, 2025 – For Women Facing Brain Tumors After Depo-Provera, the Truth Is Coming to Light

If you’ve developed a brain tumor after years of receiving Depo-Provera injections, you’re not alone—and you’re not imagining the connection. Recent research and legal action are shedding new light on the risks that thousands of women may have unknowingly faced for years.

A powerful new study from the University of British Columbia confirms that long-term use of Depo-Provera may significantly increase the risk of developing brain tumors known as intracranial meningiomas. The study found that women using the shot for over a year had more than three times the risk of developing a tumor compared to those using other birth control options. These findings align with earlier warnings and suggest that the risk remains high after extended use.

What’s even harder to accept is that Pfizer had a lower-dose alternative, called Depo Sub-Q Provera 104, which may have reduced this risk. But it was never widely promoted. Lawyers now argue this was a missed opportunity to protect patients—and a decision driven more by profit than by safety.

Many women have already stepped forward, including a recent plaintiff who used Depo-Provera for eight years and was later diagnosed with a brain tumor after experiencing numbness, double vision, and slurred speech. Her story mirrors many others and reflects what could be a much broader pattern of harm.

The judge overseeing the Depo-Provera multidistrict litigation has put systems in place to review complaints and medical evidence efficiently, while also recognizing that it can be difficult to locate old medical records. If you’re gathering documentation or unsure where to begin, know that our team of dangerous product lawyers can help.

Right now, most lawyers are focusing on the strongest and clearest cases first, usually those where women had long-term use, serious health effects, and solid medical histories. These cases are setting the stage for what comes next, and they are paving the way for other women to be heard. Reach out today for more information.

May 1, 2025 – Growing Number of Women Coming Forward

The Depo-Provera multidistrict litigation is seeing significant growth as more women bravely step forward to share their experiences. In April 2025, the MDL nearly doubled in size with 52 new cases, bringing the total to 130. A finalized short-form complaint is expected soon, which will make it easier for more women to join.

New Lawsuits from Kentucky, Tennessee, and Florida

Across the country, new lawsuits continue to shed light on the harm linked to this drug.

A woman in Tennessee shared that her long-term use of Depo-Provera resulted in the growth of multiple brain tumors, including one that required invasive brain surgery in 2013. Even after that surgery, she resumed injections and was later diagnosed with a second tumor in 2018.

In Kentucky, a woman who received Depo-Provera injections between 2001 and 2006 developed a brain tumor that left her with ongoing neurological issues, despite undergoing surgery to remove it.

A Florida woman has joined the MDL as well, alleging that Depo-Provera contributed to her bilateral hearing loss and tinnitus. Her tumor was discovered after an MRI was performed in response to her worsening symptoms.

Many of these lawsuits argue that patients were never adequately warned about the risks, even though other countries have required stronger warnings on Depo-Provera’s label for many years.

Legal Challenges with Generic Manufacturers

Authorized generic drug makers have also been scrutinized in this litigation. Recently, the court reviewed affidavits submitted by Greenstone, Viatris, and Prasco to determine their level of involvement with the drug.

It now appears that Prasco may soon be dismissed from the litigation, while Greenstone and Viatris remain active defendants. These companies will be expected to fully engage in the discovery process, and plaintiffs’ attorneys will continue seeking evidence about their roles in the marketing and distribution of Depo-Provera.

This development ensures that some women harmed by generic versions of the drug will still have a path to pursue justice.

Judge Rodgers’ Commitment to Accountability

Judge Rodgers is continuing to hold all parties to high standards of compliance. After two defendants initially failed to meet court deadlines, the judge issued an Order to Show Cause, making it clear that missing deadlines will not be tolerated.

The court’s firm approach benefits all plaintiffs by keeping the litigation moving forward efficiently and ensuring that defendants take their responsibilities seriously. In mass tort litigation, credibility and responsiveness can make a significant difference, and both sides are expected to meet the court’s expectations.

Making It Easier to Prove Depo-Provera Use

One of the biggest challenges many women face in this litigation is proving they received Depo-Provera injections, especially when records from years ago may be missing or incomplete.

To address this, the court has implemented a uniform system for gathering proof-of-use evidence. Plaintiffs now have 120 days from March 14, 2025, or the date they file, to complete a Proof of Use and Injury Questionnaire.

This new process empowers plaintiffs to request essential records from third parties like pharmacies, hospitals, clinics, insurers, and military medical systems. If necessary, subpoenas can be used to compel cooperation, ensuring that women are not unfairly denied justice simply because of missing paperwork.

April 1, 2025 – Judge Pushes Depo-Provera MDL Forward with Tight Deadlines

The Depo-Provera MDL is gaining momentum under the direction of Judge Rodgers, who recently set an aggressive schedule to keep the litigation on track. Discovery on the issue of federal preemption must be completed by July 25, 2025, with summary judgment motions due a month later. General causation discovery is set to finish in October, followed by expert witness challenges in early 2026.

In addition to the federal MDL, similar lawsuits are advancing in state courts, notably in Pennsylvania, California, and Illinois. Anticipating this, Judge Rodgers has appointed liaison counsel to help coordinate between state and federal proceedings, recognizing that some plaintiffs may pursue claims outside the MDL for strategic reasons.

With discovery now fully underway, Pfizer is required to turn over key documents by mid-May. The court’s firm deadlines and no-nonsense approach signal that delays won’t be tolerated. In mass tort litigation, serious settlement discussions typically happen when trial dates are looming—and this MDL is rapidly heading in that direction.

March 17, 2025 – Leadership Has Been Appointed for Plaintiffs in Depo-Provera MDL

Leadership has finally been named in the MDL over Pfizer’s Depo-Provera birth control injection and its alleged link to brain tumors. Dozens of experienced attorneys have joined other important subcommittees as the litigation moves forward. Plaintiffs allege the hormonal drug caused serious neurological harm, including seizures and vision loss, among other symptoms from the brain tumors.

The Depo-Provera MDL is still in its early stages, with leadership just appointed to oversee the pretrial proceedings. The MDL currently has a direct filing order in place, and five pilot cases have been selected for early discovery and trial prep. As of March 2025, at least 78 lawsuits are consolidated in the Northern District of Florida, with many more expected to come soon.

March 14, 2025 – 10 Developments Intended to Speed Up the Depo-Provera MDL — And a New Concern About Blood Clots

The Depo-Provera MDL is gaining momentum as women sue Pfizer over claims that the birth control shot led to the development of meningioma brain tumors. Attorneys for both sides have agreed on a framework designed to move the litigation forward more efficiently. Here’s what potential claimants should know:

Direct Filing Into the MDL – Plaintiffs can now file directly into the federal court system, avoiding time-consuming transfers from their local districts.
Digital Platform for Case Management – An online system will handle filings and service of documents, helping avoid paperwork delays.
Pilot Cases Selected – A group of early cases will help shape the direction of the litigation and provide insight into how future claims may unfold.
Disputes Over Expert Testimony – Plaintiffs aim to use expert witnesses to support their claims, while Pfizer is expected to push back on whether those experts are qualified.
Confidentiality Agreements in Place – The parties have agreed to protect sensitive documents shared during the case.
Initial Proof Required From Plaintiffs – Claimants will need to show they used Depo-Provera and were diagnosed with meningioma, but they’ll be given a chance to correct incomplete submissions.
Internal Pfizer Documents Must Be Shared – Plaintiffs will review company records that could reveal what Pfizer knew about potential risks and when they learned important information.
Depositions Scheduled – Plaintiffs will have the chance to question Pfizer employees, with some interviews conducted remotely and/or on video.
Dismissals for Unrelated Defendants – Companies not directly involved with a claimant’s use of the product may be removed from some lawsuits.
Oversight by a Special Master and CPA – These professionals will help manage logistics and ensure proper handling of legal fees and resources.

Although mass torts typically take time, these steps suggest the Depo-Provera litigation could progress faster than usual.

New Blood Clot Risk Raises Further Safety Questions

While the legal claims so far have focused on brain tumors, a newly reported case is drawing attention to a possible clotting risk tied to Depo-Provera. A 21-year-old woman developed a rare and life-threatening condition called Phlegmasia Cerulea Dolens (a severe type of deep vein thrombosis) shortly after receiving the injection. She suffered extensive blood clots in her leg and lungs, requiring emergency surgeries.

Although the drug label mentions clotting risks, they are often minimized—especially when compared to estrogen-based contraceptives. This case suggests Depo-Provera may cause more dangerous side effects than previously thought, even for young women without known clotting risk factors. Experts argue that Pfizer may not have fully warned doctors and patients about the severity of these risks.

March 1, 2025 – Over 30,000 Lawsuits Projected in Depo Provera MDL, Judge Issues Pretrial Order, and New Study Links Drug’s Active Ingredient to Brain Tumors

As many as 30,000 women between the ages of 18 and 55 who used Depo Provera long-term and later developed a meningioma brain tumor may have a strong argument to prove their claims in court. Women who received the birth control injection at a young age but did not develop tumors until decades later could face tougher legal challenges but may still have viable claims for compensation. Defense attorneys are expected to scrutinize these lawsuits based on each plaintiff’s medical history, proof of their Depo Provera use, and other potential causes of tumor development.

In recent weeks, the newly appointed MDL Judge, M. Casey Rodgers, issued a Pretrial Order setting the groundwork for the MDL, including establishing a Master Docket for case filings and defining procedural rules for out-of-state attorneys. Given the nationwide scope of this litigation, legal teams from across the country will be involved. Notably, Judge Rodgers has waived the usual requirement for attorneys not licensed in Florida to provide a Certificate of Good Standing from their home state in order to participate.

All legal representatives must submit a Notice of Appearance for each case they handle and adhere to the Federal Rules of Civil Procedure regarding the proper service of legal documents. Magistrate Judge Hope T. Cannon has also been appointed to assist with the MDL. Magistrate Cannon previously worked alongside Judge Rodgers on the massive 3M earplug litigation that recently settled for $6 billion. This dynamic duo is expected to establish an efficient process for managing this case.

A recent medical study has further strengthened the link between Depo Provera’s active ingredient, medroxyprogesterone acetate (MPA), and an increased risk of meningioma brain tumors. The study examined 14 years of medical records, comparing women who used MPA-based birth control to those who took oral contraceptives. Findings revealed that women using MPA injections for over a year had a 3.55 times higher risk of developing these tumors than those who relied on birth control pills.

Despite this alarming research, the FDA has not mandated any warning labels for these risks in the United States. While the European Medicines Agency (EMA) has recommended adding meningioma risk warnings to MPA-based drugs, American patients remain uninformed about the potential dangers of long-term Depo Provera use.

February 11, 2025 – Depo-Provera MDL Assigned to Northern Florida

In a surprising move, the Judicial Panel on Multidistrict Litigation (JPML) has assigned the Depo-Provera MDL to the Northern District of Florida, selecting Judge M. Casey Rodgers to oversee the litigation. Many expected the case to land in California, where most lawsuits were originally filed, or New York, home to Pfizer, but the panel prioritized experience over geography. Judge Rodgers previously managed the massive 3M earplug litigation that resulted in a $6 billion settlement.

This decision has several key implications for plaintiffs. First, proceedings are likely to move quickly, as Judge Rodgers is known for keeping cases on track and limiting delays. Second, the jury pool in Northern Florida may not be as plaintiff-friendly as California, but it is still considered a fair venue for litigation. Third, the discovery process is expected to be streamlined, reducing the likelihood of Pfizer using common delay tactics to wear plaintiffs down.

With the MDL now set, the next steps include leadership appointments, discovery schedules, and early case management orders. While bellwether trials are still a long way off, this ruling sets the stage for how the litigation will unfold. Stay tuned for further updates.

February 1, 2025 – MDL Panel Decision Pending as Key Legal Arguments Take Shape

As we await the Multidistrict Litigation (MDL) Panel’s decision on where these cases will be consolidated (see our previous update), the defendants are continuing to advocate for New York as a more appropriate venue than the Plaintiffs’ proposed location in California. Meanwhile, Pfizer is positioning itself to argue a federal preemption defense. The company asserts that it cannot be held liable for failing to warn users about potential meningioma brain tumors because the FDA denied its request to include such a warning on the Depo Provera product label.

Both parties involved in this litigation agree that an MDL is the most efficient mechanism to manage the growing number of Depo Provera lawsuits. The advantages of MDL proceedings include:

• Streamlined discovery processes and collaborative evidence sharing
• Coordinated motion hearings, leading to consistent judicial rulings
• The ability for plaintiffs to pool resources for stronger collective arguments while maintaining their individual claims
• Shared litigation expenses to reduce financial burdens
• The potential for a comprehensive settlement that provides equitable relief to all injured parties

Key Questions Before the MDL
The MDL will likely address several critical questions central to this litigation:

• Is there sufficient scientific evidence to establish a causal link between Depo Provera’s ingredients and the development of meningioma brain tumors?
• Did Pfizer fail to warn U.S. patients about this risk while including such warnings in European and Canadian markets?
• Were safety risks concealed during Pfizer’s business dealings with Viatris, another pharmaceutical company?
• Could the lower-dose version of Depo Provera, marketed as Depo-SubQ, have mitigated the risk of brain tumor development among users?

Your Legal Advocates Are Here to Help
If you or a loved one received Depo Provera injections and have experienced adverse effects, including the development of a meningioma brain tumor, our team at Dolman Law Group is here to provide the guidance and advocacy you need. We are committed to holding negligent corporations accountable, ensuring the safety of future patients, and securing the financial resources necessary to address ongoing medical needs. Contact us today to learn more about your rights and options.

January 1, 2025 – Proposed MDL Hearing Scheduled for January 30 as State Lawsuits Continue to Rise

The motion to establish a Depo-Provera Multidistrict Litigation (MDL) will be reviewed by the Judicial Panel on Multidistrict Litigation (JPML) on January 30, 2025, in Miami. This panel, comprised of seven federal judges appointed by Chief Justice John Roberts of the U.S. Supreme Court, will likely issue a decision soon after the hearing, possibly as early as February.

In the meantime, women are filing new lawsuits across the country claiming injuries linked to Depo-Provera injections. If the MDL is approved, many of these cases may be consolidated into this federal litigation. The dangerous drug team at Dolman Law Group is closely monitoring these developments. If you have any questions or concerns, don’t hesitate to contact us for a free consultation.

What Are the Severe Side Effects and Health Risks of Depo-Prover?

While Depo-Provera is widely used, its severe side effects have raised significant concerns. One of the most troubling health risks associated with the drug is the development of brain tumors, particularly meningiomas. Meningiomas are typically benign, but their growth can lead to pressure on the brain or spinal cord, causing symptoms such as headaches, blurred vision, seizures, and numbness. In some cases, surgical removal is necessary, which poses additional risks to the patient.

A recent study published in The BMJ revealed that women who used Depo-Provera for 12 months or more had a 5.6-fold increased risk of developing meningiomas. This link between the drug and brain tumors has led many to file lawsuits, arguing that they were not adequately informed about the potential dangers.

In addition to the risk of brain tumors, long-term Depo-Provera use can cause significant bone density loss, leading to osteoporosis. This risk is exceptionally high for younger women who start using the drug before their bones are fully developed. Even after stopping Depo-Provera, some women struggle to regain lost bone density, increasing their risk of fractures and long-term skeletal issues.

Other health risks include severe mood swings, depression, and anxiety, all of which have been reported by Depo-Provera users. The hormonal changes brought on by the drug can interfere with emotional stability, affecting the quality of life. Weight gain is another frequently mentioned side effect, contributing to further health complications for some users.

Lawsuits Against Depo-Provera Manufacturers

The serious health risks associated with Depo-Provera have prompted many women to take legal action against the drug’s manufacturer, Pfizer. The primary claims in these lawsuits focus on the failure to adequately warn patients about two key risks: the development of meningiomas (brain tumors) and significant bone density loss, which can lead to osteoporosis.

The increased risk of brain tumors, especially meningiomas, is a focal point of these lawsuits. Studies have shown that extended use of Depo-Provera raises the likelihood of developing these tumors, which, although typically benign, can cause significant neurological problems and require invasive surgeries. Plaintiffs argue that Pfizer did not provide enough information about this risk, which has resulted in severe consequences for many women.

Bone density loss is another central issue in these legal actions. Long-term Depo-Provera users have reported experiencing substantial bone mineral loss, leading to conditions like osteoporosis and fractures. Many of these plaintiffs contend that had they been adequately warned about this side effect, they might have chosen alternative contraceptive methods. Although Pfizer has updated its warnings about bone density loss, the damage was already done for many women.

These lawsuits fall under product liability law, with plaintiffs claiming that Pfizer failed to provide necessary warnings about the risks of Depo-Provera. Some cases are handled as part of a class action or multidistrict litigation (MDL), where plaintiffs with similar claims can streamline the legal process by consolidating common issues. This allows for quicker resolutions while addressing each individual’s specific damages.

As more information about the dangers of Depo-Provera comes to light, the number of lawsuits is expected to grow, with women seeking justice and compensation for the harm caused by the drug.

Compensation and Legal Recourse for Depo-Provera Victims

For those affected by Depo-Provera’s severe side effects, legal action may offer a way to recover compensation for the harm they have endured. Women harmed by the drug may seek compensation for several types of damages, including medical costs, lost income, and the emotional toll of living with the side effects.

Medical Expenses
One of the primary forms of compensation sought in Depo-Provera lawsuits is the recovery of medical expenses. For victims of meningiomas, these costs can include diagnosis, treatment, brain surgery, and long-term monitoring. 

Even though meningiomas are generally benign, they still require careful medical attention to prevent complications. Additionally, those dealing with bone density loss may need long-term medical care, such as medications, physical therapy, and, in severe cases, surgery to repair fractures caused by osteoporosis.

Lost Income
Victims often seek compensation for the wages and income lost during recovery from surgeries or long-term health complications. Women who undergo brain surgery for meningiomas or who suffer from debilitating osteoporosis may face long periods of recovery, during which they cannot work. Some victims might never be able to return to their previous jobs due to the lasting impact of their injuries. In such cases, compensation for lost income can make a critical difference in a person’s financial well-being.

Pain and Suffering
Beyond the financial costs, Depo-Provera’s side effects can significantly affect a person’s quality of life. The physical pain and discomfort from bone density loss, along with the recovery from brain surgery, can be intense and prolonged. 

Psychological suffering is also common, especially for those dealing with long-term health problems like anxiety or depression stemming from the drug’s side effects. Lawsuits often include claims for pain and suffering, aiming to compensate victims for their emotional and physical challenges.

Punitive Damages
In cases where it is proven that Pfizer acted recklessly or failed to warn consumers adequately, courts may also award punitive damages, which can significantly increase the compensation available to victims.

Class Actions and Multidistrict Litigation (MDL)
Many Depo-Provera lawsuits are pursued through class actions or multidistrict litigation (MDL). These legal approaches allow multiple plaintiffs with similar claims to join forces, streamlining the legal process and helping courts address common issues efficiently. 

In a class action, plaintiffs share any settlement or judgment, while in an MDL, individual plaintiffs retain more control over their specific damages, even though the cases are handled together. Both options can provide a faster path to compensation for those affected by Depo-Provera.

Victims of Depo-Provera’s side effects should work with experienced attorneys to explore their legal options and pursue the compensation they need and deserve.

How Dolman Law Group Can Help

If Depo-Provera has harmed you or a loved one, seeking legal recourse can feel overwhelming. The attorneys at Dolman Law Group are here to help guide you through the legal process and fight for the compensation you deserve. Our team has a proven track record of taking on large pharmaceutical companies like Pfizer, holding them accountable for the harm caused by dangerous drugs.

At Dolman Law Group, we provide personalized, expert legal representation to victims of defective drugs like Depo-Provera. 

Our product liability attorneys will explain the legal steps you need to take, help you gather critical evidence, and determine the best course of action—whether pursuing an individual lawsuit or joining a multidistrict litigation (MDL).

We understand the serious physical, emotional, and financial toll that can come with a meningioma diagnosis or other health complications related to Depo-Provera. That’s why we’re committed to seeking compensation for medical expenses, lost wages, pain and suffering, and other damages on your behalf.

With Dolman Law Group, you’ll have a dedicated legal team that provides clear guidance and aggressive representation at every case stage. We aim to ensure you receive the justice and compensation you need and deserve.

If you or a loved one has experienced severe side effects from Depo-Provera, contact Dolman Law Group today for a free consultation. We’ll help you understand your legal options and get started on the path to recovery.